Table 1 Prospective clinical trials with... | American Society of Hematology

Table 1

Prospective clinical trials with RIC HSCT in CLL: conditioning regimens and outcomes

	Dreger et al^25,26 (N = 90)		Sorror et al²⁴ (N = 82)		Brown et al²⁷ (N = 76)		Khouri et al²⁸ (N = 86)		Michallet et al²⁹ (N = 40)		Schetelig et al²²* (N = 30)
	%	Years	%	Years	%	Years	%	Years	%	Years	%	Years
Conditioning regimen	Nonmyeloablative (fludarabine-cyclophosphamide with/without anti-thymocyte globulin)		Nonmyeloablative (fludarabine, low-dose total body irradiation)		Reduced-intensity (fludarabine-busulfan)		Nonmyeloablative (fludarabine-cyclophosphamide-rituximab)		Nonmyeloablative (fludarabine-cyclophosphamide-rituximab)		Nonmyeloablative (fludarabine-busulfan)
Alternative donors†	59		37		63		50		0		57
Relapse incidence	46	6	38	5	40	5	NR		22	3	33	10
Progression-free survival	38	6	39	5	43	5	36	5	46	3	43	10
OS	58	6	50	5	63	5	51	5	55	3	46	10
5-y OS of patients with sensitive disease at HSCT	69‡		70§		79\|\|		NA		NA		NA
Follow-up, y
Median	6.0		5		5.1		3.1		2.3		10
Range	0.6-10.7		0.9-7.3				0.9-10.9		0.3-5.9

	Dreger et al^25,26 (N = 90)		Sorror et al²⁴ (N = 82)		Brown et al²⁷ (N = 76)		Khouri et al²⁸ (N = 86)		Michallet et al²⁹ (N = 40)		Schetelig et al²²* (N = 30)
	%	Years	%	Years	%	Years	%	Years	%	Years	%	Years
Conditioning regimen	Nonmyeloablative (fludarabine-cyclophosphamide with/without anti-thymocyte globulin)		Nonmyeloablative (fludarabine, low-dose total body irradiation)		Reduced-intensity (fludarabine-busulfan)		Nonmyeloablative (fludarabine-cyclophosphamide-rituximab)		Nonmyeloablative (fludarabine-cyclophosphamide-rituximab)		Nonmyeloablative (fludarabine-busulfan)
Alternative donors†	59		37		63		50		0		57
Relapse incidence	46	6	38	5	40	5	NR		22	3	33	10
Progression-free survival	38	6	39	5	43	5	36	5	46	3	43	10
OS	58	6	50	5	63	5	51	5	55	3	46	10
5-y OS of patients with sensitive disease at HSCT	69‡		70§		79\|\|		NA		NA		NA
Follow-up, y
Median	6.0		5		5.1		3.1		2.3		10
Range	0.6-10.7		0.9-7.3				0.9-10.9		0.3-5.9

NA, not applicable; NR, not reached.

J.S., unpublished observations.

Donors other than HLA-identical siblings.

Unpublished data, GCLLSG on file.

Nonbulky disease, HCT-CI, 0; n=34.

Jenifer Brown and Haesook Kim, personal communication, September 6, 2013.